InMed Pharmaceuticals

InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need

InMed's (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer's With A Rare Cannabinoid Analog

InMed Pharmaceuticals, A Cannabinoid-Focused Company, Sponsored Benzinga's Cannabis Capital Conference

InMed's (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer's With A Rare Cannabinoid Analog

InMed Pharmaceuticals, A Cannabinoid-Focused Company, Sponsored Benzinga's Cannabis Capital Conference

This Clinical Stage BioPharma Is Seeing Solid Growth In Rare Cannabinoid Demand From The Health And Wellness Sector

Despite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023

This Clinical Stage BioPharma Is Seeing Solid Growth In Rare Cannabinoid Demand From The Health And Wellness Sector

Despite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023

This Company's Rare Cannabinoids May Hold Promise In The Treatment Of Neurodegenerative Diseases Like Alzheimer's

InMed Pharmaceuticals: The Clinical-Stage Company Setting Sites On Dominating Rare Cannabinoid Production And Commercialization Across Global Markets

InMed Pharmaceuticals Recent News

InMed Pharmaceuticals To Acquire BayMedica, Rare Cannabinoid Manufacturer, For ~$3.66M

InMed Pharmaceuticals (NASDAQ: INM) announced on Monday that it has entered into a definitive agreement to acquire BayMedica Inc., a private company that manufactures rare cannabinoids.